Is FULC or SVRA more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -25.38% -24.15% Savara N/A -90.28% -68.95%

Does the media prefer FULC or SVRA?

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Savara. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Fulcrum Therapeutics' score of 0.41 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor FULC or KURA?

In the previous week, Kura Oncology had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.41 beat Kura Oncology's score of 0.32 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FULC or SLDB more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Fulcrum Therapeutics N/A -25.38% -24.15% Solid Biosciences N/A -71.35% -60.58%

Does the media prefer FULC or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Fulcrum Therapeutics. Solid Biosciences' average media sentiment score of 0.91 beat Fulcrum Therapeutics' score of 0.41 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVTX or FULC more profitable?

Fulcrum Therapeutics' return on equity of -25.38% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Fulcrum Therapeutics N/A -25.38% -24.15%

Does the media refer more to AVTX or FULC?

In the previous week, Avalo Therapeutics had 7 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 3 mentions for Fulcrum Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Fulcrum Therapeutics' score of 0.41 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate FULC or CVAC?

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 115.79%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Fulcrum Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 4 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Fulcrum Therapeutics (FULC) Competitors

$3.80 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.80 +0.01 (+0.13%)

As of 09/11/2026 04:10 PM Eastern

Compare

FULC vs. SVRA, KURA, SLDB, AVTX, and CVAC

Should you buy Fulcrum Therapeutics stock or one of its competitors? Fulcrum Therapeutics's main competitors and comparable companies include Savara (SVRA), Kura Oncology (KURA), Solid Biosciences (SLDB), Avalo Therapeutics (AVTX), and CureVac (CVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fulcrum Therapeutics compare to Savara?

Fulcrum Therapeutics (NASDAQ:FULC) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Fulcrum Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.62	-$74.88M	-$1.21	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Fulcrum Therapeutics' return on equity of -25.38% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Savara	N/A	-90.28%	-68.95%

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than Savara. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Fulcrum Therapeutics' score of 0.41 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Fulcrum Therapeutics presently has a consensus target price of $8.20, suggesting a potential upside of 115.79%. Savara has a consensus target price of $10.00, suggesting a potential upside of 88.68%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Fulcrum Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market. Comparatively, Savara has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Summary

Fulcrum Therapeutics beats Savara on 9 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Kura Oncology?

Fulcrum Therapeutics (NASDAQ:FULC) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Fulcrum Therapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.62	-$74.88M	-$1.21	N/A
Kura Oncology	$67.48M	15.02	-$278.67M	-$3.37	N/A

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Fulcrum Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Fulcrum Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Fulcrum Therapeutics' return on equity of -25.38% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Kura Oncology	-384.30%	-207.18%	-45.17%

Fulcrum Therapeutics currently has a consensus price target of $8.20, indicating a potential upside of 115.79%. Kura Oncology has a consensus price target of $25.40, indicating a potential upside of 123.00%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Kura Oncology had 5 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 3 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.41 beat Kura Oncology's score of 0.32 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fulcrum Therapeutics beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Solid Biosciences?

Fulcrum Therapeutics (NASDAQ:FULC) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Fulcrum Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.62	-$74.88M	-$1.21	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Fulcrum Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 115.79%. Solid Biosciences has a consensus target price of $18.18, indicating a potential upside of 108.99%. Given Fulcrum Therapeutics' higher probable upside, equities research analysts plainly believe Fulcrum Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Fulcrum Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulcrum Therapeutics' return on equity of -25.38% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Solid Biosciences	N/A	-71.35%	-60.58%

In the previous week, Solid Biosciences had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Fulcrum Therapeutics. Solid Biosciences' average media sentiment score of 0.91 beat Fulcrum Therapeutics' score of 0.41 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulcrum Therapeutics beats Solid Biosciences on 9 of the 13 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Fulcrum Therapeutics' return on equity of -25.38% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Fulcrum Therapeutics	N/A	-25.38%	-24.15%

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 179.78%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 115.79%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Avalo Therapeutics had 7 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 10 mentions for Avalo Therapeutics and 3 mentions for Fulcrum Therapeutics. Avalo Therapeutics' average media sentiment score of 0.83 beat Fulcrum Therapeutics' score of 0.41 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	14,408.59	-$78.26M	-$4.37	N/A
Fulcrum Therapeutics	$80M	3.62	-$74.88M	-$1.21	N/A

Avalo Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the broader market.

Summary

Fulcrum Therapeutics beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to CureVac?

Fulcrum Therapeutics (NASDAQ:FULC) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

CureVac has a net margin of 199.92% compared to Fulcrum Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Fulcrum Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 0 mentions for CureVac. Fulcrum Therapeutics' average media sentiment score of 0.41 beat CureVac's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Fulcrum Therapeutics	Neutral
CureVac	Neutral

CureVac has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.62	-$74.88M	-$1.21	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Fulcrum Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

Fulcrum Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 115.79%. Given Fulcrum Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Fulcrum Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Fulcrum Therapeutics beats CureVac on 9 of the 15 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$289.93M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	N/A	14.18	274.94	25.36
Price / Sales	3.62	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	0.59	15.12	10.33	6.20
Net Income	-$74.88M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-1.30%	-4.34%	-3.32%	-2.35%
1 Month Performance	2.43%	0.54%	-0.53%	-3.23%
1 Year Performance	-45.71%	40.74%	23.51%	8.79%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	2.1935 of 5 stars	$3.80 flat	$8.20 +115.8%	-45.7%	$289.93M	$80M	N/A	100
SVRA Savara	2.1508 of 5 stars	$5.53 +3.0%	$10.14 +83.4%	+48.9%	$1.14B	N/A	N/A	20	Positive News
KURA Kura Oncology	3.5146 of 5 stars	$12.52 -5.5%	$25.40 +102.9%	+39.1%	$1.11B	$77.23M	N/A	130
SLDB Solid Biosciences	2.0337 of 5 stars	$9.93 -3.1%	$18.18 +83.1%	+61.4%	$1.06B	N/A	N/A	100	News Coverage Gap Down
AVTX Avalo Therapeutics	3.4565 of 5 stars	$19.71 +2.5%	$45.10 +128.8%	+51.4%	$1.06B	$60K	N/A	40	News Coverage Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. SVRA, KURA, SLDB, AVTX, and CVAC

How does Fulcrum Therapeutics compare to Savara?

Summary

How does Fulcrum Therapeutics compare to Kura Oncology?

Summary

How does Fulcrum Therapeutics compare to Solid Biosciences?

Summary

How does Fulcrum Therapeutics compare to Avalo Therapeutics?

Summary

How does Fulcrum Therapeutics compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. SVRA, KURA, SLDB, AVTX, and CVAC

How does Fulcrum Therapeutics compare to Savara?

Which has higher valuation and earnings, FULC or SVRA?

Is FULC or SVRA more profitable?

Do institutionals and insiders hold more shares of FULC or SVRA?

Does the media prefer FULC or SVRA?

Do analysts prefer FULC or SVRA?

Which has more volatility & risk, FULC or SVRA?

Summary

How does Fulcrum Therapeutics compare to Kura Oncology?

Which has better earnings & valuation, FULC or KURA?

Do institutionals and insiders have more ownership in FULC or KURA?

Which has more volatility & risk, FULC or KURA?

Is FULC or KURA more profitable?

Do analysts rate FULC or KURA?

Does the media favor FULC or KURA?

Summary

How does Fulcrum Therapeutics compare to Solid Biosciences?

Which has better valuation and earnings, FULC or SLDB?

Do analysts prefer FULC or SLDB?

Which has more risk & volatility, FULC or SLDB?

Do insiders and institutionals believe in FULC or SLDB?

Is FULC or SLDB more profitable?

Does the media prefer FULC or SLDB?

Summary

How does Fulcrum Therapeutics compare to Avalo Therapeutics?

Is AVTX or FULC more profitable?

Do analysts prefer AVTX or FULC?

Do insiders & institutionals believe in AVTX or FULC?

Does the media refer more to AVTX or FULC?

Which has better valuation and earnings, AVTX or FULC?

Which has more risk and volatility, AVTX or FULC?

Summary

How does Fulcrum Therapeutics compare to CureVac?

Is FULC or CVAC more profitable?

Does the media prefer FULC or CVAC?

Which has preferable earnings and valuation, FULC or CVAC?

Do insiders and institutionals believe in FULC or CVAC?

Which has more volatility & risk, FULC or CVAC?

Do analysts rate FULC or CVAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools